

Phase 1 clinical study of first in class tie2 activator PMC-403 in patients with age-related macular degeneration

PharmAbcine Inc.



OPHTHALMOLOGY	Phase 1
Product Type	Therapeutic Antibody
Indication	Neovascular Age-related Macular Degeneration (nAMD)
Target	Tie2 receptor
MoA(Mechanism of Action)	Tie2 receptor agonist
Competitiveness	Tie2 activation repairs and stabilizes leaky retinal and choroidal blood vessels, which differs from anti-VEGF agents. Targeting a novel Tie2 pathway improving vessel integrity can overcome the limitation of anti-VEGF therapy. PMC-403 can be developed to become the first-in-class therapeutics to treat neovascular eye diseases including wet AMD, diabetic retinopathy and diabetic macular edema.
Development Stage	Phase 1
Route of Administration	Intravitreal injection